Volver al Panel








Regeneron Pharmaceuticals, Inc. (REGN)
Valores intradiarios en tiempo real
Resumen del Mercado
From:
To:
REGN Intraday
No data available
SímboloREGN
Fecha de SalidaApr 2, 1991
CEODr. Leonard S. Schleifer M.D., Ph.D.
Empleados a Tiempo Completo15.4k
SectorHealthcare
IndustriaBiotechnology
PaísUnited States
BolsaNasdaqGS
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. The company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. It also has a strategic collaboration with CytomX Therapeutics, Inc. to create conditionally-activated bispecific cancer therapies. It has a strategic alliance with Sanofi to develop long-acting immunology antibodies. The company was incorporated in 1988 and is based in Tarrytown, New York.
Rendimiento
| Período | Rentabilidad % | Cambio de Valor |
|---|---|---|
| 1 Día | -0.23% | -2.12 US$ |
| 5 Días | -3.58% | -34.25 US$ |
| 1 Mes | +14.34% | +115.55 US$ |
| 6 Meses | +44.19% | +282.34 US$ |
Analizando el Mercado con IA
Evaluando los últimos 30 días de historial y métricas fundamentales de REGN...
Estadísticas Clave
Cap. de Mercado
95.24B
Relación P/E
20.35
Rend. de Div.
0.41%
Máx. 52 Semanas
$991.73
Mín. 52 Semanas
$591.52
Consenso de Analistas
CONSENSOCompra
ALCISTA1967.9%
NEUTRAL932.1%
BAJISTA00.0%
Objetivos de Precios de Analistas a 52 Semanas
Objetivo Mín.
$812.00
$812.00
Objetivo Máx.
$1175.00
$1175.00
Actual$921.22
Objetivo Prom.$991.00
Recomendaciones de Analistas
Precio Objetivo:$991.00($812.00 - $1175.00)
¿Buscas más valores? Explóralos en el screener
Pensamientos de la Comunidad
Comparta su análisis y sentimiento sobre REGN
Únase a la comunidad para compartir su análisis
Últimas Noticias para REGN

Has Vertex Stock Become A Different Bet?
Trefis•20 nov 2026, 12:28
Argus Adjusts Price Target on Regeneron Pharmaceuticals to $1,050 From $850
MT Newswires•20 nov 2026, 12:10

Sanofi and Regeneron’s rare disease wins; Lilly’s dealmaking dance
Pharma Voice•19 nov 2026, 21:52

Alnylam (ALNY) Stock Looks Undervalued As Shares Fell 68%
Simply Wall St.•19 nov 2026, 18:17

2 Growth Stocks to Buy in November Without Any Hesitation
Motley Fool•19 nov 2026, 18:03

Alnylam Pharmaceuticals (ALNY) Stock Dropped, So What Is Driving Attention Now?
Simply Wall St.•19 nov 2026, 16:08

With FDA nod, Regeneron brings an RNAi drug to autoimmune disease
BioPharma Dive•19 nov 2026, 15:10

REGN Gets FDA Nod for Livsayis in Generalized Myasthenia Gravis
Zacks•19 nov 2026, 14:42
Goldman Sachs Adjusts Regeneron Pharmaceuticals PT to $1,115 From $1,110
MT Newswires•19 nov 2026, 14:01

Regeneron Wins FDA Nod For Livsayis, 4x-Year GMG Shot
Benzinga•19 nov 2026, 13:10